Abstract Library

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#4351 Outcomes of lobar and sub-lobar resection for lung neuroendocrine tumours (LNETs, carcinoids) – An ENETS CoE experience

Introduction: LNETs are rare tumours accounting for 1–2% of all lung cancers.

Conference:

Presenting Author:

Authors: Hojerat R, Idaiss I, Aviel G, Korach A, Bel-Ange A,

Keywords: lung neuroendocrine tumour, pulmonary carcinoid, lobar resection, sub-lobar resection, pro-gastrin-releasing peptide,

#4242 Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

Introduction: Everolimus and Sunitinib are often used consecutively for advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET), but to date no data on the optimal sequence is available.

Conference:

Presenting Author: Islam O

Authors: Islam O, van de Vyver G, Verslype C, Borbath I, Decaestecker J,

Keywords: pNEN, Everolimus, Sunitinib, mPFS, mOS, AEs,

#4222 Quali-NET: A prospective study on patient-reported quality of life in neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms of the lung (LNEN) or gastro-enteropancreatic tract (GEPNEN) are typically slow-growing, leading to longer overall survival, and resembling chronic illnesses. Therefore, focus on quality of life (QoL) is crucial. While brief studies have been done, comprehensive, long-term studies are needed.

Conference:

Presenting Author: Islam O

Authors: Islam O, Depauw L, van der Massen I, Simoens M, Galdermans D,

Keywords: GEP-NEN, LNEN, Quality of life, Longitudinal data,

#4165 Detecting NET using Methylation-based biomarkers and the novel IMPRESS technology

Introduction: Due to current limitations, diagnosis of neuroendocrine tumors (NETs) is frequently delayed. Addressing this issue is crucial, necessitating the identification of new, adequate biomarkers. Our previous work highlighted the methylome as a promising source of biomarkers, enabling differentiation of NET vs. non-NET samples, and distinguishing based on tissue of origin (TOO).

Conference:

Presenting Author: Mariën L

Authors: Mariën L, Ibrahim J, Islam O, Chhajlani S, Neefs I,

Keywords: neuroendocrine tumor, DNA methylation, biomarker selection, IMPRESS technology,